Lolly
06-01-2004, 02:06 PM
Hi Lyn, GREAT NEWS!
I found a good article from CancerConsultant's coverage of the San Antonio Breast Cancer Symposium last year; it addresses the triplet regimen you're starting, but I couldn't find a reference to length of time, will keep looking. Here's a quote from the article which I found VERY encouraging for all of us.
- ANTIBODY-BASED REGIMENS -
"The use of trastuzumab (Herceptin®) as the backbone of treatment for patients with overexpression of the HER2 gene and amplification of the HER2 protein product has transformed the approach to the subgroup of patients expressing this phenotype. Indeed, from a group of patients with the worst prognosis and greatest resistance to chemotherapy, HER2 positive patients receiving Herceptin® and chemotherapy have the highest response rate and survival. It appears that the use of targeted therapy against this relevant biologic receptor has substantially altered the natural history of the disease."
Christine reported this same information to us after she and Joe attended the conference, and here it is in black and white!
I found a good article from CancerConsultant's coverage of the San Antonio Breast Cancer Symposium last year; it addresses the triplet regimen you're starting, but I couldn't find a reference to length of time, will keep looking. Here's a quote from the article which I found VERY encouraging for all of us.
- ANTIBODY-BASED REGIMENS -
"The use of trastuzumab (Herceptin®) as the backbone of treatment for patients with overexpression of the HER2 gene and amplification of the HER2 protein product has transformed the approach to the subgroup of patients expressing this phenotype. Indeed, from a group of patients with the worst prognosis and greatest resistance to chemotherapy, HER2 positive patients receiving Herceptin® and chemotherapy have the highest response rate and survival. It appears that the use of targeted therapy against this relevant biologic receptor has substantially altered the natural history of the disease."
Christine reported this same information to us after she and Joe attended the conference, and here it is in black and white!